Table 1 Patients and treatment characteristics
N (%) | |
|---|---|
Sex | |
Male | 24 (86) |
Female | 4 (14) |
Age | |
Mean | 56.8 |
Range | 31-78 |
Comorbidities | |
Diabetes | 1 (3.5) |
Heart failure | 5 (18) |
Tumor site | |
Oral cavity | 8 (28.5) |
Nasopharynx | 1 (3.5) |
Oropharynx | 11 (39.5) |
Hypopharynx | 1 (3.5) |
Larynx | 6 (21.5) |
Salivary glands | 1 (3.5) |
Hystology | |
SCC | 27 (96.5) |
Adenoid cystic | 1 (3.5) |
Grading | |
G1 | 2 (7) |
G2 | 8 (28.5) |
G3 | 13 (46.5) |
NA | 5 (18) |
RT setting | |
Definitive RT | 14 (50) |
Adjuvant RT | 14 (50) |
Highest prescribed dose | |
70 Gy | 13 (46.5) |
68 Gy | 2 (7) |
64 Gy | 8 (28.5) |
60 Gy | 5 (18) |
Combination therapy | |
Neoadjuvant CT | |
TPF x 3 | 5 (18) |
CBDCA + TAX x 3 | 4 (14) |
Concurrent CT | |
Weekly CDDP | 14 (50) |
Weekly CBDCA | 8 (28.5) |
None (exclusive RT) | 6 (21.5) |